Literature DB >> 17576860

A replacement for warfarin: the search continues.

John W Eikelboom, Jeffrey I Weitz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576860     DOI： 10.1161/CIRCULATIONAHA.107.712349

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

1.  The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.

Authors:  Dorien Groenendaal; Gregory Strabach; Alberto Garcia-Hernandez; Takeshi Kadokura; Marten Heeringa; Roelof Mol; Charlotte Eltink; Hartmut Onkels
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  New options with dabigatran etexilate in anticoagulant therapy.

Authors:  Lars Maegdefessel; Joshua M Spin; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

3.  RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

Authors:  Ph Gabriel Steg; Shamir R Mehta; J Wouter Jukema; Gregory Y H Lip; C Michael Gibson; Frantisek Kovar; Petr Kala; Alberto Garcia-Hernandez; Ronny W Renfurm; Christopher B Granger
Journal:  Eur Heart J       Date:  2011-08-30       Impact factor: 29.983
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.